BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3